Oncology Ventures Closes $62M Fund II on Healthcare Bet

Oncology Ventures closed its second fund at $62 million this week, landing above its initial target and signaling that specialized healthcare venture capital still has momentum even as broader VC fundraising remains choppy. The Miami-based firm, which launched in 2021, focuses exclusively on early-stage companies developing cancer diagnostics, therapeutics, and care delivery models.

The oversubscribed close — Fund II exceeded its original $55 million target — comes as life sciences venture activity shows signs of recovery after two years of retrenchment. While overall venture fundraising fell 30% in 2025 according to PitchBook data, healthcare-focused funds bucked the trend, posting modest gains as institutional investors rotate back into defensive sectors with clearer regulatory pathways and binary outcomes.

Oncology Ventures didn't disclose its LP base, but the firm indicated that Fund II drew commitments from family offices, healthcare-focused institutional investors, and strategic corporate backers with stakes in the oncology supply chain. That mix suggests the fund is positioning itself not just as capital, but as a connector — linking portfolio companies to commercial partners, clinical trial infrastructure, and eventual acquirers in big pharma.

The $62 million pool will target pre-seed through Series A investments, with check sizes ranging from $500,000 to $5 million per company. Oncology Ventures plans to deploy the fund over the next three years, reserving roughly 40% for follow-on investments in breakout portfolio companies. The firm's strategy leans toward precision oncology, immunotherapy platforms, and diagnostic tools that promise earlier detection or better treatment personalization.

Oncology Ventures' ability to raise Fund II above target hinges largely on what it's done with Fund I. The firm's inaugural $28 million vehicle, closed in 2021, backed 14 companies across diagnostics, drug development, and digital health. While most remain private and pre-revenue, at least three have advanced to later-stage funding rounds led by larger institutional VCs — an important signal that the firm can pick companies other investors want in on.

One Fund I portfolio company, a liquid biopsy startup focused on minimal residual disease detection, raised a $40 million Series B last year from a top-tier Silicon Valley health-tech fund. Another, developing CAR-T cell therapy enhancements, secured a partnership with a major academic medical center that's now running early-phase trials. Those outcomes — partnerships, follow-on rounds, clinical milestones — matter more in life sciences venture than hypergrowth revenue curves.

The firm also points to its advisory network as a differentiator. Oncology Ventures maintains a bench of oncologists, clinical trial specialists, and former pharma executives who work with portfolio companies on study design, regulatory strategy, and commercial positioning. That's table stakes in healthcare VC now, but it's especially critical in oncology, where the gap between a promising preclinical result and an approvable product is wide and expensive.

Still, Fund I is young. The oldest investments are just over four years old, and exit timelines in life sciences venture typically stretch seven to ten years. Oncology Ventures hasn't yet returned capital to LPs, and none of its portfolio companies have reached a liquidity event. The oversubscribed Fund II close suggests investors are betting on momentum and access, not proven returns.

The broader life sciences venture landscape is stabilizing after a rough 2023 and 2024. Deal volume dropped nearly 40% from 2021 peaks, and valuations compressed as public biotech indices cratered. Companies that raised at inflated valuations during the pandemic funding boom faced painful down rounds or shut down entirely. But 2025 brought early signs of thaw: IPO windows cracked open for a handful of well-capitalized biotechs, and M&A activity picked up as pharma companies looked to replenish depleted pipelines.

Oncology remains the single largest therapeutic area for venture investment, capturing roughly 35% of all life sciences deal flow in 2025 according to SVB Securities data. That's partly because cancer is a massive market — global oncology drug sales topped $200 billion in 2024 — and partly because regulatory pathways for cancer therapies are relatively well-trodden. The FDA grants more breakthrough designations and accelerated approvals in oncology than any other category.

But investor appetite is narrowing. Early-stage life sciences funds are writing fewer checks and concentrating capital in companies with de-risked assets — those with human data, clear IP, or partnerships already in place. Platform plays and preclinical-stage therapeutic companies are getting passed over unless the science is genuinely novel or the team has multiple exits under their belts.

Oncology Ventures is betting that its focus — only cancer, only early-stage — gives it an edge in pattern recognition and network depth that generalist health-tech funds can't match. Whether that thesis holds depends on whether the firm can consistently pick the 2-3 companies per vintage that return the fund. In venture, especially life sciences venture, one or two outliers drive all the returns. The rest either limp along or shut down quietly.

Oncology Ventures operates out of Miami, which isn't an obvious home base for a life sciences VC. The city lacks the deep biotech clusters of Boston, the Bay Area, or San Diego. But Miami has emerged as a secondary hub for healthcare services, medical devices, and health-tech over the past five years, fueled by pandemic-era migration of investors and founders, favorable tax treatment, and proximity to Latin American markets and clinical trial sites.

Oncology Ventures says Fund II will prioritize three themes: precision diagnostics that enable earlier cancer detection, next-generation immunotherapies that improve on CAR-T and checkpoint inhibitors, and care delivery models that reduce the cost and complexity of administering cancer treatment. That's a wide aperture, but it reflects where venture dollars are flowing across the oncology stack.

Precision diagnostics is arguably the hottest subsector right now. Liquid biopsy companies — which detect cancer DNA fragments in blood — are racing to prove their tests can catch tumors at Stage I or even pre-cancerous stages. Grail, Guardant Health, and Exact Sciences have spent billions building the category, and now a wave of venture-backed challengers is trying to carve out niches by geography, cancer type, or payer channel.

Immunotherapy remains the single largest area of oncology R&D investment, but the bar for differentiation is rising. CAR-T therapies work, but they're expensive, hard to manufacture, and only effective in certain blood cancers. Solid tumors remain largely resistant. Oncology Ventures is looking for companies that solve manufacturing bottlenecks, expand CAR-T to solid tumors, or combine immunotherapy with other modalities like radiotherapy or small molecules.

The care delivery angle is less obvious but potentially more capital-efficient. Cancer treatment is moving out of hospitals and into outpatient infusion centers, home health settings, and even patients' homes via oral therapies. Companies that reduce the friction and cost of administering biologics — think logistics, pharmacy services, patient monitoring — can scale faster and exit sooner than drug developers.

Oncology Ventures hasn't named specific companies it's already invested Fund II capital in, but the firm indicated it's already deployed roughly 15% of the fund into three companies since the close. Expect those names to surface over the coming quarters as the companies raise follow-on rounds or announce partnerships.

The firm declined to name individual LPs, but its investor mix skews toward family offices with healthcare backgrounds, endowments with life sciences allocations, and a handful of corporate strategics that operate in adjacent markets — think diagnostics companies, pharmacy benefit managers, and healthcare real estate investors. That LP composition matters because it gives Oncology Ventures access to commercial partnerships and pilot customers for its portfolio companies, not just capital.

Oncology Ventures charges a standard 2% management fee and 20% carry, with a preferred return threshold typical for early-stage venture funds. The firm expects to invest Fund II over a three-year deployment period, with reserves held back for follow-on rounds in top performers. That's a disciplined pace — not the spray-and-pray model that got some generalist funds in trouble during the 2021-22 boom.

Here's the harder question no press release answers: Can oncology-focused venture funds consistently return 3-5x multiples in an environment where exit valuations have compressed and IPO windows remain narrow? Life sciences venture is littered with funds that picked good companies but couldn't get them to liquidity at the right time. Timing matters as much as picking.

Oncology Ventures is placing two bets. First, that pharma M&A will remain active as large drugmakers face patent cliffs on blockbuster oncology drugs and need to acquire innovation rather than develop it internally. That's a safe bet — pharma has been a reliable acquirer of oncology assets for two decades. Second, that the IPO market for biotech will recover enough by 2028-2030 to provide a viable exit path for later-stage portfolio companies. That's less certain.

The firm also faces the challenge every specialist fund faces: deal access. Oncology is crowded with well-capitalized venture investors, from legacy life sciences funds like Arch Venture Partners and Flagship Pioneering to newer entrants backed by sovereign wealth funds. Oncology Ventures is competing for deals against firms with bigger balance sheets, deeper benches, and longer track records. Its edge has to come from speed, sector expertise, or willingness to take earlier risk than larger funds.

The oversubscribed close suggests LPs believe Oncology Ventures has found that edge. Whether it holds up over the next five years depends on exits, not announcements.

The most interesting companies in oncology right now aren't coming out of traditional academic labs. They're being founded by former pharma executives who've seen what works and what doesn't inside big companies, by computational biologists applying AI to drug discovery, and by clinicians frustrated with the gap between cutting-edge research and what actually gets used in practice. Oncology Ventures says it's looking for those founders — not just the ones with the best publications.

That's smart positioning, but it's also what every early-stage fund says. The proof will be in the portfolio composition two years from now. Are the companies solving real clinical problems, or are they chasing investor buzzwords? Are they building for exits, or are they building for ego? Those questions won't get answered in a press release.

Oncology Ventures' $62 million Fund II sits squarely in the mid-tier range for specialized life sciences venture funds. It's smaller than the mega-funds raised by Flagship Pioneering ($3.6 billion in 2023) or ARCH Venture Partners ($3 billion in 2024), but larger than the boutique $20-30 million vehicles raised by single-GP life sciences investors. That size gives the firm flexibility to lead seed rounds and participate in Series A rounds without getting priced out or diluted into irrelevance.

The firm's closest comparables are other thesis-driven, early-stage life sciences funds: Rock Health for digital health, 8VC's Bio Fund for computation-driven drug discovery, Khosla Ventures' life sciences practice for moonshot therapeutics. What differentiates Oncology Ventures is its singular focus on cancer across the entire value chain — diagnostics, therapeutics, and care delivery. Most funds pick one layer of the stack. Oncology Ventures is betting that understanding all three gives it better pattern recognition.

The risk is that spreading across diagnostics, therapeutics, and services dilutes expertise rather than enhancing it. A diagnostic company and a cell therapy company have almost nothing in common operationally. Different regulatory pathways, different commercial models, different timelines to revenue. The firm will need to prove it can add value across all three, not just write checks.

Oncology Ventures declined to provide IRR data or portfolio performance metrics for Fund I, which is standard for a fund still in its early years. The firm did say that 12 of its 14 Fund I companies remain active and funded, which is a decent survival rate for early-stage life sciences venture. Most seed-stage biotech companies fail or pivot before reaching meaningful milestones.

The firm's deployment pace will be a key metric to watch. If Oncology Ventures burns through Fund II in 18 months, it suggests either deal flow is abundant or discipline is lacking. If deployment stretches past four years, it could signal the firm is struggling to find quality companies at reasonable valuations. The three-year target the firm laid out is reasonable, but the real test is whether they stick to it.

Life sciences venture is cyclical, tied to public market biotech indices, FDA approval trends, and pharma M&A appetites. Oncology Ventures is raising Fund II during a recovery phase, but that doesn't mean smooth sailing ahead. If public biotech indices crater again — and they will, eventually — private valuations will follow. Companies that raised at high marks in 2026-27 will face down rounds or shutdowns.

The firm's ability to weather that volatility depends on three things: reserve discipline, portfolio construction, and LP patience. If Oncology Ventures reserves enough capital to support its winners through a downturn, it can avoid the trap of letting portfolio companies die for lack of bridge funding. If it builds a diversified portfolio across therapeutic modalities and commercial timelines, it reduces single-point-of-failure risk. And if its LPs are long-term oriented and understand life sciences venture cycles, they won't panic and pull future commitments when marks drop.

Those are big ifs. Most early-stage venture funds fail at least one of those three tests. The fact that Oncology Ventures raised Fund II oversubscribed suggests its LPs are optimistic. But optimism in venture capital is forward-looking. The real measure is what happens when a portfolio company's clinical trial fails, or when a key hire leaves, or when a competitor launches a better product six months earlier.

Oncology Ventures didn't address those scenarios in its announcement, which is fine — no one does. But they're the scenarios that determine whether a $62 million fund becomes a $180 million fund in five years or quietly disappears from the LP pitch circuit.

The press release doesn't name a single portfolio company, which is standard for early-stage funds that don't want to tip their hand to competitors or spook stealth-mode founders. But it leaves the most important question unanswered: What does an Oncology Ventures portfolio company actually look like?

Is the firm backing academic spinouts with strong IP but no commercial experience? Serial entrepreneurs launching their third oncology company? Former pharma executives building what they wish existed inside their old employers? Each archetype comes with different risks and different paths to exit. A fund's portfolio construction reveals more about its strategy than any thesis deck.

What's clear is that Oncology Ventures is betting on volume. With $62 million deployed over three years at $500k-$5M per company, the firm will back somewhere between 12 and 25 companies depending on follow-on reserves. That's a classic seed-stage venture portfolio: broad enough to capture outliers, concentrated enough to support winners.

The next 18 months will reveal whether the firm can sustain deal flow at that pace, and whether the companies it backs look like tomorrow's category leaders or today's also-rans. Fundraising announcements are the easy part. Building a portfolio that returns capital is the part that happens in silence.